Shopping Cart
Remove All
Your shopping cart is currently empty
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | In Stock | In Stock | |
| 5 mg | $863 | Inquiry | Inquiry | |
| 10 mg | $1,380 | Inquiry | Inquiry |
| Description | Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD). |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Uniprot ID |
| Molecular Weight | 149.19KD |
| Cas No. | 347396-82-1 |
| Relative Density. | no data available |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.